Nordea Investment Management AB lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 19.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 67,546 shares of the biotechnology company’s stock after purchasing an additional 10,815 shares during the quarter. Nordea Investment Management AB owned about 0.07% of Sarepta Therapeutics worth $8,228,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nkcfo LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at approximately $43,000. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. UMB Bank n.a. grew its holdings in shares of Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 197 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $59,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.
Sarepta Therapeutics Stock Up 1.4 %
Analysts Set New Price Targets
Several brokerages have commented on SRPT. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Needham & Company LLC cut their price target on Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday, November 27th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, December 19th. Finally, Guggenheim increased their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $178.71.
Read Our Latest Report on Sarepta Therapeutics
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Stories
- Five stocks we like better than Sarepta Therapeutics
- How to Invest in the FAANG Stocks
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Invest in Insurance Companies: A Guide
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.